MiMedx Group, Inc., the emerging regenerative medicine company using human amniotic tissue and patent-protected procedures to establish and market advanced products and therapies for the Wound Care, Spine, Orthopedic, Ophthalmic, Surgical, Sports Medicine, and Dental sectors of healthcare, today declared that the Company’s EpiFix® product has acquired coverage from insurer Aetna Inc. effective December 23, 2016. MiMedx EpiFix Acquires Coverage from Insurer Aetna.
With this coverage decision, the almost 17.5 million Aetna commercial members now have coverage for EpiFix. Aetna believes EpiFix medically important for treatment of partial and full-thickness neuropathic diabetic foot ulcers (DFUs) that are higher than 6 weeks in duration with no capsule, tendon or bone exposed, when utilized in conjunction with standard diabetic ulcer care. MiMedx EpiFix Acquires Coverage from Insurer Aetna.
Parker H. “Pete” Petit, Chairman and CEO stated that, “We’re very glad to have got coverage from Aetna and with the important progress we’ve made in gaining coverage for our allografts from both the commercial, as well as the federal and state payers. We consider we’ve substantial opportunities ahead as we sustain to grow our advanced wound care products and broaden the other therapies and market sectors we serve with our allografts. Gaining coverage from entire commercial payers has been a crucial method for MiMedx. From our perspective, attainment of EpiFix coverage for the huge majority of the commercial covered lives has been a key contributor to the victory we’ve experienced in acquiring and exceeding our growth projections.”
Bill Taylor, President and COO, said, “The clinical efficacy and cost effectiveness of tissues and products are extremely scrutinized by the commercial health policies. It is obvious to us that the evidence indicating that our allografts benefit their members clinically, as well as give more cost effective care, has been an important factor in our success in attaining coverage awards from insurers. We know the positive clinical and economic victory our allografts have on their covered populations, and we’re always glad when health policies come to this similar conclusion.”
“Involving Aetna, we now have over 200 commercial health plans representing more than 198 million covered lives offering insurance coverage. Within the more than 200 commercial health plans, Blue Cross/Blue Shield plans encompassing forty-seven states plus the District of Columbia also give insurance coverage for their members. In regard to the commercial health plans, 40.3 million Medicare and 55.4 million Medicaid beneficiaries have insurance coverage for our allografts,” summarized Petit. MiMedx EpiFix Acquires Coverage from Insurer Aetna.
The post MiMedx EpiFix Acquires Coverage From Insurer Aetna appeared first on Healthcare Insurance News.